Literature DB >> 21052529

Reduced fructosamine-3-kinase activity and its mRNA in human distal colorectal carcinoma.

M Notarnicola, Maria G Caruso, V Tutino, V Guerra, S Frisullo, D F Altomare, G Misciagna.   

Abstract

Fructosamine-3-Kinase (FN3K) is an enzyme phosphorilating fructoselysine (FL) residues on glycated proteins, resulting in the production of protein-bound FL-3-phosphate. The pathological role of the non-enzymatic modification of proteins by reducing sugars has become increasingly evident in various types of disorders, including the cancer. In this study, our aim was to study FN3K enzyme activity, as well as its mRNA in human colorectal cancer (CRC). Thirty consecutive CRC patients undergoing surgery of the colon were enrolled in the study. FN3K enzymatic activity and gene expression were analyzed using a radiometric assay and quantitative RT-PCR, respectively. FN3K is a functionally active enzyme in human colon tissue, without significant differences between normal mucosa and cancer. The mean level of FN3K mRNA was significantly lower in cancer than in the corresponding normal colorectal mucosa The colorectal tumors located on the left side showed lower levels of both enzymatic activity and mRNA FN3K than tumors located in the right side of colon. This paper is the first studying FN3K enzyme activity in human CRC, showing a significant relationship between enzymatic activity, its mRNA and tumor side.

Entities:  

Keywords:  Colorectal cancer; Fructosamine-3-kinase activity; Gene expression; Glycation

Year:  2010        PMID: 21052529      PMCID: PMC2935531          DOI: 10.1007/s12263-009-0165-y

Source DB:  PubMed          Journal:  Genes Nutr        ISSN: 1555-8932            Impact factor:   5.523


  28 in total

1.  Biochemistry and molecular cell biology of diabetic complications.

Authors:  M Brownlee
Journal:  Nature       Date:  2001-12-13       Impact factor: 49.962

2.  Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis.

Authors:  M Shinohara; P J Thornalley; I Giardino; P Beisswenger; S R Thorpe; J Onorato; M Brownlee
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

Review 3.  Lilly Lecture 1993. Glycation and diabetic complications.

Authors:  M Brownlee
Journal:  Diabetes       Date:  1994-06       Impact factor: 9.461

4.  Increased farnesyltransferase activity in human colorectal cancer: relationship with clinicopathological features and K-ras mutation.

Authors:  M G Caruso; M Notarnicola; M Bifulco; C Laezza; V Guerra; D F Altomare; V Memeo; D Lorusso; I Demma; A Di Leo
Journal:  Scand J Gastroenterol       Date:  2003-01       Impact factor: 2.423

Review 5.  Colorectal cancer, one entity or three.

Authors:  Feng-ying Li; Mao-de Lai
Journal:  J Zhejiang Univ Sci B       Date:  2009-03       Impact factor: 3.066

Review 6.  Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disorders.

Authors:  Sho-ichi Yamagishi; Seiji Ueda; Seiya Okuda
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

7.  The comparison of the risk factors and clinical manifestations of proximal and distal colorectal cancer.

Authors:  Sung-Wook Oh; Young-Ho Kim; Yong Sung Choi; Dong Kyung Chang; Hee Jung Son; Poong-Lyul Rhee; Jae J Kim; Jong Chul Rhee; Seong-Hyeon Yun; Woo-Yong Lee; Ho-Kyung Chun; Duk-Hwan Kim; Sang Goon Shim
Journal:  Dis Colon Rectum       Date:  2007-11-21       Impact factor: 4.585

8.  Serum fructosamine and colorectal adenomas.

Authors:  Giovanni Misciagna; Giampietro De Michele; Vito Guerra; Anna M Cisternino; Alfredo Di Leo; Jo L Freudenheim
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

9.  EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma.

Authors:  C Messa; F Russo; M G Caruso; A Di Leo
Journal:  Acta Oncol       Date:  1998       Impact factor: 4.089

Review 10.  Modulation of in vivo 3-deoxyglucosone levels.

Authors:  T R Brown; B Su; K A Brown; M A Schwartz; A M Tobia; F Kappler
Journal:  Biochem Soc Trans       Date:  2003-12       Impact factor: 5.407

View more
  3 in total

1.  Low red blood cell levels of deglycating enzymes in colorectal cancer patients.

Authors:  Maria Notarnicola; Maria Gabriella Caruso; Valeria Tutino; Vito Guerra; Giovanni Misciagna
Journal:  World J Gastroenterol       Date:  2011-01-21       Impact factor: 5.742

Review 2.  The Taming of Nuclear Factor Erythroid-2-Related Factor-2 (Nrf2) Deglycation by Fructosamine-3-Kinase (FN3K)-Inhibitors-A Novel Strategy to Combat Cancers.

Authors:  Narasimha M Beeraka; Venugopal R Bovilla; Shalini H Doreswamy; Sujatha Puttalingaiah; Asha Srinivasan; SubbaRao V Madhunapantula
Journal:  Cancers (Basel)       Date:  2021-01-14       Impact factor: 6.639

3.  Evaluation of Fructosamine 3-kinase and Glyoxalase 1 activity in normal and breast cancer tissues.

Authors:  Tooba Yousefi; Abdol Rahim Gholizadeh Pasha; Ghodsieh Kamrani; Ailin Ebrahimzadeh; Ali Zahedian; Karimollah Hajian-Tilaki; Mohammad Aghajani; Durdi Qujeq
Journal:  Biomedicine (Taipei)       Date:  2021-09-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.